Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications. The biotechnology company said the FDA put a hold on its ...

SEED Therapeutics announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease and Orphan Drug designations to ...

Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...

Minovacca plans to hire UNL students to work on submitting an Investigational New Drug Application to the U.S. Food and Drug Administration, a request to administer an investigational drug to ...

Kelun-Biotech’s novel ADC drug SKB445 receives NMPA approval to treat advanced solid tumours: Chengdu Sichuan Province, PRC Friday, January 24, 2025, 15:00 Hrs [IST] Sichuan Kel ...

Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to ...